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THE ‘‘MARROW-MINER’’: EFFICACY OF A NOVEL, MINIMALLY INVASIVE
BONE MARROW HARVESTING DEVICE IN PRE-CLINICAL EVALUATION &
FIRST HUMAN EXPERIENCE
Kraft, D.L.1, Song, L.2, Crocker, M.4, Moseley, A.2, Long, M.2,
Vina, R.3, Ghazarossian, V.4 1Stanford University School of Medicine,
Stanford, CA; 2Stryker Orthopaedics; 3DRFV Foundation; 4StemCor
Systems.
Introduction: Bone marrow (BM) contains a rich supply of adult
stem and progenitor cells, and may have long-term advantages over
PBSC for many allo-transplants. Traditional percutaneous large
bore needle aspiration methods for harvesting marrow are crude, te-
dious and expensive and usually require general anesthesia. A novel
device, the MarrowMiner (MM) was developed for the minimally
invasive harvest of BM to enable the rapid, convenient, outpatient
harvest of large quantities of BM under local anesthesia for use in
BMT and an increasing array of regenerative therapies. The MM
has been tested extensively in human cadavers, in large animals, &
following recent FDA 510(k) approval, in initial human subjects.
Methods: In 5 juvenile pigs, standard 1 and 6-port needles were
used to aspirate marrow along the left iliac crest. On the right iliac,
the MM device was used to collect BM. Harvests were collected in:
small (5 ml), medium (6–20 ml), & large (.20 ml) volumes. BM vi-
ability, cell counts & CFU-F assays were performed. Initial human
subjects similarly had traditional needle harvests performed, fol-
lowed by MM harvest on their opposite hip.Results: In the porcine
study the MM was observed to be safe, with the catheter remaining
within the marrow cavity in up to 20 cm long passes..60 ml of mar-
row could be aspirated in a single pass. BM aspirated along the iliac
crest by the MM contained a significantly higher concentration of
nucleated cells and CFU/ml than by standard needles. As expected,
the CFU concentration decreased with increasing volume aspirated
by standard needles while no CFU dilution occurred with the MM.
The MM yielded significantly higher CFU/ml than the standard
needles with medium and large volume aspirates, where the MM
harvested 9 fold more CFU-F/ml than the 6-port needle (table).
In initial human subject experience, the MM was safe, effectively
collected BM, with no post-procedure pain or complications, and
higher CD341 counts compared to needle aspirates. Conclusions:
In a porcine model, the MM can successfully & safely harvest large
volumes of BM, with significantly higher stem cell content than tra-
ditional needle aspiration. The flexible shaft allowed for aspirating
BM of the highest cellularity along the iliac crest, a path unfeasible
for rigid needles. These results, as well as initial, ongoing clinical
studies suggest that this novel MM device may enable significantly
improved BM harvest in a more rapid, reproducible & less invasive
manner.
CFU/ml Content of Marrow from Traditional Harvest Aspirates and
from MarrowMiner
1 hole 6 hole MarrowMiner
Aspirate Size needle needle (MM)Small Volume 1111 ND ND
Medium Volume 516 1690 2623
Large Volume ND 226 2335
Along Ileac Crest NA NA 5313Mean CFU-F/ml (five, 65–75kg juvenile pigs).114
THE RATIO OF COLONY FORMING UNIT (CFU) TO TOTAL NUCLEATED
CELL (TNC) COUNT PREDICTS ENGRAFTMENT IN UMBILICAL CORD
BLOOD TRANSPLANT
Triplett, B.M., Regan, D.,Wofford, J., Schaeffler, J., Ferguson,W. Car-
dinal Glennon Children’s Medical Center, Saint Louis, MO.
Umbilical cord blood (UCB) is increasingly utilized as a graft
source for hematopoietic cell transplant; however, both graft failure
and delayed engraftment remain significant obstacles to successfulUCB transplantation. Graft characteristics correlated with im-
proved engraftment and survival include total nucleated cell dose
(TNC), degree of HLA match, CD341 cell dose, and colony-form-
ing unit assays (CFU). While TNC has been considered the most
consistent predictor of engraftment and survival, analysis of the rel-
ative contribution of these variables is complicated by the strong
correlation between TNC, CD341, and CFU doses. We hypothe-
size that the ratio of CFU to TNC is a cell dose-independent mea-
sure of graft hematopoietic potential that may be prognostically
useful in future graft selection algorithms.
The Saint Louis Cord Blood Bank has been performing CFU as-
says on all UCB units since 1996. Since 2002 the CFU/TNC ratio
has been utilized in our storage eligibility algorithm, with units hav-
ing\2 colonies/104 nucleated cells considered ineligible for bank-
ing. Engraftment data was analyzed for 237 acute leukemia patients
.10 kg who received a single UCB transplant after myeloablative
conditioning, and grouped into quartiles according to post-process-
ing CFU/TNC ratio. Patients without evidence of engraftment
were censored at day 60.
Median time to neutrophil engraftment (ANC . 500) became
shorter with each advancement in quartile (Table 1), and was 7
days faster in the highest CFU/TNC quartile compared to the low-
est (p 5 0.0007). A similar trend was seen in 66 patients with post-
thaw CFU data available. There was no difference in TNC dose,
degree of HLA match, or patient age amongst the four quartile
groups. CD341 cell dose was greater in the highest CFU/TNC
quartile compared to the lowest (P\ 0.05).
Several authors have shown a relationship between higher CFU
dose and faster engraftment. However, higher CFU dose is corre-
lated with higher TNC dose. This, in addition to inherent variabil-
ity in CFU testing, has led to the use of TNC dose but not CFU
dose for determining the best graft for use in UCB transplant.
We show that CFU/TNC ratio can be a powerful independent pre-
dictor of rapid engraftment. Further study will be required to deter-
mine if this parameter will allow identification of grafts with
relatively small cell doses that might still have the potential for suc-
cessful engraftment.
Table 1. Time to Neutrophil engraftment by CFU/TNC ratio
Post Processing Median Time to
Ratio Group n ANC . 500 (days)\6.0/104 57 26
6.0–7.7/104 58 24
7.7–9.3/104 62 21
.9.3/104 57 19115
COST EFFECTIVENESS OF COLLECTION STRATEGIES FOR CD341 PRO-
GENITOR CELL DETERMINATIONS IN AUTOLOGOUS HEMATOPOIETIC
PROGENITOR CELL TRANSPLANTATION
Griffin, D.L.1, Donnenberg, A.D.2, Smith, K.J.3 1University of Pitts-
burgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Cancer
Institute, Pittsburgh, PA; 3University of Pittsburgh School of Medicine,
Pittsburgh, PA.
Background: Peripheral CD34 counts can optimize timing for
collection of adult mobilized hematopoietic progenitor cell
(HPC) products for transplantation to treat hematological malig-
nancies. The ability to accurately predict a successful CD34 col-
lection can reduce the number of multiple low-CD341
collections, easing the burden of collection for the patient and
the collection and processing facilities. Our hypothesis is that in-
creasing the circulating CD341 threshold will result in a cost
savings over strategies of no threshold and the current threshold
of 4 CD341 cells/ml, while resulting in a greater proportion of
successful collections. Methods: A decision tree was programmed
in TreeAge Pro Suite 2006 v1.3 (TreeAge Software, Williams-
town, MA) and a cost analysis run comparing ‘‘no threshold’’ to
varying thresholds. Probabilities were determined from a dataset
Poster Session I 45that included all autologous HPC Transplant (HPCT) patients
with hematological malignancies seen by our HPCT program
from February 2003 to January 2007. Costs were compiled from
the Institution’s Charge Description Master and included costs
from additional filgrastim administration through collection.
The threshold was increased incrementally from 4 to 9 CD341
cells/ml to determine the most cost effective strategies while max-
imizing the number of successful collections. Results: There were
302 autologous patients with 463 peripheral CD34 assays and 572
collections. Of these, 149 patients and 322 observations had
CD341 counts\21 CD341 cells/ml. 175/322 were assays with
collections, while 147 were assay only. The analysis of the decision
tree indicates that at a CD341 level of 7, the costs of the collection
are moderately reduced by 3.3%, and 87% of the patients meet the
minimum cell goal. At a level of 8 CD341 cells/ml, the costs are re-
duced 4.5% and 100% of patients meet the minimum cell goal.
Discussion:The results suggest that the most cost effective collec-
tion occurs at peripheral CD341 count of 8 CD341 cells/ml or
above. This is not unexpected, as better collectors have fewer col-
lections. However, this results in an unacceptably high number of
patients that will fail to collect.116
DETERMINING FINAL APHERESIS VOLUME FOR HEMATOPOIETIC PRO-
GENITOR CELL (HPC) COLLECTION BASED ON INTRA-PROCEDURAL
SAMPLING
Hackett, M., Rahn, D., Smilee, R.C., Anasetti, C., Fernandez, H.,
Janssen, W.E. H. Lee Moffitt Cancer Center, Tampa, FL.
When collecting HPC by apheresis, sufficient CD34 cells must
be collected to effect a timely and stable graft. Donor safety must
also be protected, requiring that apheresis not be longer than nec-
essary. A correlation between circulating and collected CD34 cells
has been reported, but variability between donors in apheresis col-
lection efficiency may limit the accuracy of this measure for deter-
mining blood volume to process. Apheresis efficiency and
circulating CD34 cell levels must be similar throughout the collec-
tion procedure. Thus, we hypothesized that CD34 cell collection,
measured early in the apheresis process, could be used to extrapolate
the final apheresis volume needed to meet collection targets. In 47
normal HPC donors, undergoing apheresis using the Gambro
Spectra and PBSC protocol version 6.1, the collection bag was sam-
pled after one (n 5 18) or two (n 5 29) total body blood volumes
(TBV) had been processed. CD34 cells collected was determined,
and total apheresis volume was projected as:
Final apheresis vol. 5 vol. at sampling  [CD34 required/CD34
at sampling]
To insure adequate collection, apheresis was continued until
a blood volume at least 10% greater than projected was processed.
Even so, three collections (6%) failed to meet targets. To determine
the validity of the hypothesis that CD34 count at early sampling
predicts final CD34 content, dependent only on apheresis volume,
expected CD34 content for the final volume actually collected was
computed as
Expected CD34 5 sample CD34  [vol. collected/vol. at
sampling]
and was compared to the observed final CD34/Kg content. Using
simple linear regression and correlation analysis to measure the
strength of the association between the expected and the observed
CD34/Kg content, significant linearity between expected CD34
content and observed CD34 content for both 1xTBV and 2xTBV
sampling was found, with Pearson correlation coefficients of
0.914 and 0.945 respectively. F-test revealed p\0.0001 for projec-
tions from both sampling intervals. In comparison, similar analysis
comparing projected CD34 collection from circulating CD34 cells
yielded a Pearson correlation coefficient of 0.754 with F-test p\
0.0001. These results support the practice of using the CD34 con-
tent of samples drawn from partially collected products, as early in
apheresis processing as 1–2TBV, to compute the necessary donor
blood volume to process to achieve sufficient HPC collection with-
out undue risk to the donor.117
CHARACTERISTICS AND CELL COMPOSTION OF PRIVATELY BANKED
AUTOLOGOUS UMBILICAL CORD BLOOD (UCB) UNITS UTILIZED FOR
AUTOLOGOUS UCB INFUSION IN CHILDREN WITH TYPE 1 DIABETES
Smith, L., Haller, M.J., Staba Kelly, S. University of Florida, Gaines-
ville, FL.
Private cord blood banks process and store umbilical cord blood
(UCB) for potential future use by that child or perhaps a sibling.
Despite increasing numbers of UCB units banked in private banks,
very few have ever been used besides those banked intentionally for
siblings with high risk malignancies or other diseases treated with
stem cell transplant (SCT). There is high variability in the charac-
teristics, cell dose, as well as processing and storage of the UCB
units in these banks. Families pay fees for the banking and continued
storage of the units, unaware of the number of cells or other char-
acteristics of the UCB unit that is banked. At the University of Flor-
ida a study of autologous UCB infusion in children with newly
diagnosed type 1 diabetes (T1D) is underway. Children with T1D
who happened to have UCB stored at birth received an infusion
of their autologous UCB that was thawed in standard fashion.
The UCB units were all tested prior to infusion for viability, steril-
ity, and identity confirmation via HLA typing, and standard cell
enumeration and flow cytometry were performed. Twelve children
have had their autologous UCB infused at a median age of 6 (range
2–10) years. Eleven of the UCB units were stored in 8 private banks
and 1 unit had been donated to a public bank and was retrieved for
the study. The median weight of patients was 24 (range 12–45) kg.
The average nucleated cell dose per kilogram infused was 1.89 107
(range 0.27–4.39), with an average CD34 dose per kilogram of 4.4
104 and viability of 96%. At most transplant centers, the minimum
desired cell dose for standard UCB transplant is 3 107 per kg body
weight. Of the 12 UCB units, only 3 would have exceeded this min-
imum, despite the fact that the average weight was only 24 kg. One
of the 3 units of sufficient size was the unit that had actually been
banked in the public bank. In addition, half of the units were stored
in cryovials ranging from 0.5 ml to 5 mls. The vials leave no room to
add any media for the thawing process. This resulted in a 15% de-
crease in recovery when compared with units stored in bags. In ad-
dition, the risk of bacterial contamination is higher when the cells
are in vials and have to be transferred to larger vials or bags for pro-
cessing and infusion. Private UCB banks advertise to families to
store a child’s UCB for future use, charging a significant fee, how-
ever it appears that many units may be under the acceptable cell dose
for standard transplant.
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ELEVATED CD141 CELL DOSE IN MARROW GRAFT CORRELATES WITH
INCREASED MORTALITY AFTER ALLOGENEIC TRANSPLANTATION
Arpinati, M.1, Chirumbolo, G.1, Nicolini, B.1, De Vivo, A.1,
Bonifazi, F.1, Giannini, M.B.1, Bandini, G.1, Martelli, V.1,
Stanzani, M.1, Baccarani, M.1, Rondelli, D.2 1University of Bologna,
Bologna, Italy; 2University of Illinois at Chicago, Chicago, IL.
Background: The role of donor antigen presenting cells (APC)
in human bone marrow grafts in post-transplant clinical outcome
is not well established, although data from animal models suggest
that they may regulate GVH responses and immune reconstitution
early after transplant. Aim: In this retrospective study we tested
whether marrow composition of donor APC was associated with
outcome after allogeneic transplantation. Patients and Methods:
81 consecutive patients undergoing allogeneic bone marrow trans-
plantation in our institution from June 1999 through June 2006
were analyzed, provided that graft composition data were available.
All but 1 patient received the marrow from HLA matched unrelated
donors. Of 81 patient, 67 received a myeloablative and 14 a reduced
intensity conditioning regimen. ATG was also administered in 79/
81 patients. Graft numbers of CD11c1 myeloid DC (mDC),
CD1231 plasmacytoid DC (pDC) and CD141 monocytes were
determined based on flow cytometry analysis. Results: After a me-
dian follow up of 346 days (interquartile 132–968), the following
transplant-related events were recorded: acute GVHD II-IV in 18
and extensive chronic GVHD in 22 patients and relapse in 19 pa-
tients. Transplant-related mortality (TRM) occurred in 23, and re-
lapse-related mortality in 12 patients. Patients were divided based
